Abbott receives FDA clearance for AI-powered coronary imaging platform
Tweet Send to a Friend
Abbott (NYSE: ABT) received U.S. Food and Drug Administration clearance and CE Mark for its Ultreon 3.0 Software, an artificial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
